Company news
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news
Iovance Biotherapeutics, Inc. news releases on 6ix. Latest, Jul 10, 2023: Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
Press releases — page 2
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 9, 2023
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
July 9, 2023
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
July 9, 2023
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
June 14, 2023
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
May 25, 2023
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 8, 2023
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
May 1, 2023
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
March 23, 2023
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
February 27, 2023
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
February 20, 2023
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
January 22, 2023
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
November 17, 2022
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 9, 2022
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
November 2, 2022
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
October 9, 2022
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
August 24, 2022
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
August 3, 2022
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
June 12, 2022
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
May 25, 2022
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates
May 4, 2022
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
April 4, 2022
Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
March 14, 2022
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
February 23, 2022
Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team
January 9, 2022
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 12, 2021
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 11, 2021
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 8, 2021
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates
November 3, 2021
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
September 27, 2021
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
September 22, 2021
Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates
August 4, 2021
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
June 28, 2021
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
June 5, 2021
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
June 3, 2021
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting
May 18, 2021
Iovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates
May 5, 2021
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
April 8, 2021
Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer
March 14, 2021
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
February 24, 2021
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
December 13, 2020
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates
November 4, 2020
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
October 4, 2020
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
August 5, 2020
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering
June 1, 2020
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
May 27, 2020
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
May 26, 2020
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
May 12, 2020
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
May 4, 2020
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
February 24, 2020
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
January 14, 2020